ストックスクリーナーアプリを入手
150.99
0.64%
-0.98
プレマーケット:
150.83
-0.16
-0.11%
前日終値:
$151.97
開ける：
$151.4
24時間の取引高:
1.23M
Relative Volume:
0.55
時価総額：
$288.11B
収益：
$54.72B
当期純損益:
$14.02B
株価収益率:
21.01
EPS:
7.1855
ネットキャッシュフロー:
$15.32B
1週間 パフォーマンス:
-2.25%
1か月 パフォーマンス:
+3.40%
6か月 パフォーマンス:
+14.57%
1年 パフォーマンス:
+36.20%
1日の値動き範囲:
$150.77
$152.04
1週間の範囲:
$149.38
$155.04
52週間の値動き範囲:
$104.93
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, AZN, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
150.99 | 288.11B | 54.72B | 14.02B | 15.32B | 7.1855 |
LLY
Lilly Eli Co
|
919.90 | 821.80B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
230.69 | 555.64B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
203.71 | 360.31B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.69 | 311.24B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
117.10 | 289.22B | 64.93B | 18.26B | 12.36B | 7.2751 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | アップグレード | Argus | Hold → Buy |
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2026-01-06 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-12-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-09-12 | ダウングレード | Goldman | Neutral → Sell |
| 2025-08-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | ダウングレード | UBS | Buy → Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Underweight |
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
Novartis AG stock (CH0012005267): Is its innovative drug pipeline strong enough to unlock new upside - AD HOC NEWS
Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight - GlobeNewswire Inc.
Novartis AG (MEX:NVSN) Bonds - GuruFocus
Novartis AG stock (CH0012005267): Is its focused pharma strategy strong enough to unlock new upside? - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): Why Google Discover changes matter more now - AD HOC NEWS
Novartis AG Stock Operating Data - GuruFocus
Novartis AG (ADR) stock (CH0012005267): Why its innovative drug pipeline matters more now for invest - AD HOC NEWS
Novartis AG (ADR) stock (CH0012005267): Why does its innovative drug pipeline matter more now for in - AD HOC NEWS
NVS Stock Quote Price and Forecast - CNN
Book value per share of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView — Track All Markets
Novartis AG stock (CH0012005267): Is its Innovative Medicines focus strong enough to unlock new upsi - AD HOC NEWS
NVS Technical Analysis | Trend, Signals & Chart Patterns | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG stock: Why Fabhalta momentum matters for investors now - AD HOC NEWS
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030 - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors - ChartMill
Novartis AG stock: What investors should know about its steady pharma powerhouse status - AD HOC NEWS
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG (NVS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com
Novartis AG (ADR) Stock: Resilient Pharma Leader with Strong Fundamentals and Growth Potential for N - AD HOC NEWS
Novartis AG Stock: Resilient Pharma Leader with Strong Fundamentals and Strategic Growth Ahead for I - AD HOC NEWS
Novartis AG Stock Historical Valuations - GuruFocus
Novartis Bolsters Immunology Pipeline With Excellergy Deal - Zacks Investment Research
Dow Jones Top Company Headlines at 11 AM ET: Novartis to Buy Excellergy for Up to $2 Billion | Why ... - 富途牛牛
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy - Proactive Investors
Novartis AG Stock: Strong Analyst Upgrades and Pipeline Momentum Drive Investor Interest in 2026 - AD HOC NEWS
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors - ChartMill
Novartis AG (NVS) Bonds - GuruFocus
Novartis AG stock gains 2% on SIX Swiss Exchange amid strong SMI performance and positive pharma sec - AD HOC NEWS
Novartis AG stock surges on Bank of America price target hike amid strong pharma pipeline momentum - AD HOC NEWS
Novartis AG Stock Faces Pressure Amid Multi-Billion Oncology Acquisition and Pipeline Advances - AD HOC NEWS
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 - ChartMill
Novartis AG Stock Gains Traction on Analyst Upgrades and Oncology Pipeline Momentum in 2026 - AD HOC NEWS
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting - Novartis
Novartis AG stock dips on Swiss Exchange amid $3B breast cancer drug acquisition announcement - AD HOC NEWS
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline - ChartMill
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrades and Pipeline Momentum - AD HOC NEWS
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
1.65%
大文字化:
|
ボリューム (24 時間):